{
  "id": "64281a47690f196b5100004f",
  "type": "yesno",
  "question": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?",
  "ideal_answer": "Yes, OXLUMO (lumasiran) is approved for the treatment of primary hyperoxaluria type 1 (PH1) in adults and children aged 6 years and older.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33789010",
    "http://www.ncbi.nlm.nih.gov/pubmed/34154993",
    "http://www.ncbi.nlm.nih.gov/pubmed/34022071",
    "http://www.ncbi.nlm.nih.gov/pubmed/33985991",
    "http://www.ncbi.nlm.nih.gov/pubmed/35237473",
    "http://www.ncbi.nlm.nih.gov/pubmed/35747094",
    "http://www.ncbi.nlm.nih.gov/pubmed/33497125",
    "http://www.ncbi.nlm.nih.gov/pubmed/34906487",
    "http://www.ncbi.nlm.nih.gov/pubmed/35731461",
    "http://www.ncbi.nlm.nih.gov/pubmed/33513899",
    "http://www.ncbi.nlm.nih.gov/pubmed/35843439",
    "http://www.ncbi.nlm.nih.gov/pubmed/33405070",
    "http://www.ncbi.nlm.nih.gov/pubmed/35015123"
  ],
  "snippets": [
    {
      "text": "Lumasiran (Oxlumo\u2122) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33405070",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OXLUMO (lumasiran) for the treatment of primary hyperoxaluria,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34154993",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conjugation of oligonucleotide therapeutics, including small interfering RNAs (siRNAs) or antisense oligonucleotides, to N-acetylgalactosamine (GalNAc) ligands has become the primary strategy for hepatocyte-targeted delivery, and with the recent approvals of GIVLAARI (givosiran) for the treatment of acute hepatic porphyria, OXLUMO (lumasiran) for the treatment of primary hyperoxaluria, and Leqvio (inclisiran) for the treatment of hypercholesterolemia, the technology has been well validated clinically.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34154993",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this context we discuss nedosiran (Dicerna Pharmaceuticals, Inc.) and lumasiran (Alnylam Pharmaceuticals), which are both novel RNAi therapies for primary hyperoxaluria that selectively reduce hepatic expression of lactate dehydrogenase and glycolate oxidase respectively, reducing hepatic oxalate production and urinary oxalate levels.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34022071",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On 23 November 2020, lumasiran was approved in the USA for the treatment of adult and paediatric patients with PH1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33405070",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33789010",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "On 19 November 2020, lumasiran received its first global approval in the EU for the treatment of PH1 in all age groups.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33405070",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efforts made to develop pharmacological treatments succeeded with the biotechnological agent lumasiran, a siRNA product against glycolate oxidase, which has become the first effective therapy to treat PH1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33513899",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34906487",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Several new drugs have been approved to treat rare genetic disorders: setmelanotide for certain conditions causing obesity; lumasiran for primary hyperoxaluria type 1, a kidney disorder; and lonafarnib for two diseases that cause premature aging.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33497125",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747094",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35015123",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " Lumasiran was recently approved in the treatment of primary hyperoxaluria type 1 and nedosiran is in the approval process.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35731461",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: Lumasiran had an acceptable safety profile and reduced urinary oxalate excretion in all patients with primary hyperoxaluria type 1 to near-normal levels.CLINI",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33985991",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lumasiran is an RNA interference (RNAi) therapeutic agent that reduces hepatic oxalate production, which has been recently approved for the treatment of PH1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35237473",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RATIONALE & OBJECTIVE: Lumasiran reduces urinary and plasma oxalate (POx) in patients with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. ILLUMINATE-C evaluates the efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with PH1 and a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843439",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}